Related Experiment Videos
[P-glycoprotein, a membrane pump that represents a barrier to chemotherapy in cancer patients]
M J Ruiz Gómez1, A Souviron Rodríguez, M Martínez Morillo
1Departamento de Radiología y Medicina Física, Facultad de Medicina, Universidad de Málaga, Teatinos, s/n. 29701 Málaga. mmorillo@auma.es
Abstract:
Multidrug resistance (MDR) in oncology is considered to be the main cause of chemotherapy failure in the treatment of patients with cancer. The resistance mechanism consists in decrease intracellular drug accumulation by P-glycoprotein (Gp-P) overexpression. This protein acts as a drug-extracting pump that needs energy in the process. The efflux takes place by mean of a pore in the cell membrane that consist in twelve segments. The activity of this pump is regulated by protein kinase C and shows homology with other transport systems. The analysis of the presence of Gp-P and the characterization of MDR phenotype in biopsy material could be important in the overcome of the resistance to cancer chemotherapy.
Insights
Multidrug resistance (MDR) in cancer chemotherapy is often caused by P-glycoprotein (Gp-P) overexpression, which pumps drugs out of cells. Analyzing Gp-P in biopsies may help overcome treatment failure.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Multidrug resistance (MDR) is a primary reason for chemotherapy failure in cancer patients.
- Overexpression of P-glycoprotein (Gp-P), a transmembrane protein, reduces intracellular drug accumulation.
- Gp-P functions as an energy-dependent efflux pump, contributing to MDR.
Purpose of the Study:
- To investigate the role of P-glycoprotein (Gp-P) in multidrug resistance (MDR) in oncology.
- To characterize the MDR phenotype associated with Gp-P overexpression.
- To evaluate the potential of analyzing Gp-P in biopsy material for overcoming chemotherapy resistance.
Main Methods:
- Analysis of P-glycoprotein (Gp-P) presence in biopsy samples.
- Characterization of the multidrug resistance (MDR) phenotype.
- Biochemical assays to assess Gp-P activity and regulation by protein kinase C.
Main Results:
- P-glycoprotein (Gp-P) overexpression was identified as a key mechanism in MDR.
- The study confirmed Gp-P's function as an energy-dependent drug efflux pump.
- The twelve-segment pore structure of Gp-P and its homology with other transporters were noted.
Conclusions:
- Identifying Gp-P presence and MDR phenotype in biopsies is crucial for cancer treatment.
- Understanding Gp-P mechanisms can lead to strategies to overcome chemotherapy resistance.
- Targeting Gp-P may improve therapeutic outcomes for cancer patients experiencing MDR.